VARIANTS OF DR3 AND USE THEREOF

Amir Aharoni (Inventor), Itay Levin (Inventor)

Research output: Patent

Abstract

Death-domain receptor 3 (DR3) variants having increased binding affinity to TL1A, and composition comprising same, are provided. Further, methods of use of said peptides or composition, including, but not limited to treatment of autoimmune and/or inflammatory disease are provided.

Original languageAmerican English
Patent numberUS2017114118
IPCC07K 14/ 705 A I
Priority date27/04/15
StatePublished - 27 Apr 2017

Cite this